Friday 16 October 2026
Export ALEC’s income statement to Excel — free account
Alector, Inc.
ALEC Healthcare Biotechnology
Alector, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $21.0 million, down 79.1% from fiscal 2024. In the quarter to June 2026, revenue fell 57.8%, EPS grew 30.0%, free cash flow grew 30.2% and total debt rose 3.27%, each against the same quarter a year earlier.
1.84
0.07
−3.66%
Follow ALEC
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(121.98%) | (181.56%) | (238.85%) | (385.11%) | |
Piotroski F-Score |
3 | 1 | 1 | 2 | |
| (25.31%) | (37.54%) | (38.69%) | (42.15%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(46.21%) | (68.79%) | (68.13%) | (76.15%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.93) | (1.79) | (1.57) | (1.42) | |
Free Cash Flow |
(197.58) | (184.07) | (173.20) | (158.39) | |
Capital Expenditures |
(0.21) | (0.04) | (0.14) | (0.16) | |
| Other line items | |||||
Cash ROIC |
(55.12%) | (62.11%) | (76.41%) | (91.73%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
198.50% | 584.77% | 582.51% | 715.07% | |
Selling, General and Administrative Expense of Revenue |
80.63% | 256.53% | 257.19% | 297.33% | |
Share Based Compensation of Revenue |
46.38% | 126.67% | 115.19% | 120.92% | |
Operating CF/Net income |
1.83 | 1.29 | 1.38 | 1.34 | |
Depreciation/Fixed assets |
0.14 | 0.31 | 0.50 | 0.57 | |
Capex/Depreciation |
(0.12) | (0.01) | (0.03) | (0.03) | |
Revenue per Share |
0.67 | 0.20 | 0.17 | 0.12 | |
Operating CF per Share |
(1.92) | (1.79) | (1.56) | (1.42) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.01 |
Columns are period end dates